Streetbeat News

SLNO

Soleno Therapeutics, Inc.

https://soleno.life

Industry

Biotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Oppenheimer analyst Leland Gershell maintains an Outperform rating on Soleno Therapeutics (NASDAQ:SLNO) and raises the price target from $59 to $65.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:06 pm

Soleno Therapeutics (NASDAQ:SLNO) reported a Q2 EPS of $(0.57), beating the analyst consensus estimate of $(0.63) by 9.52%. This represents a 29.63% improvement over the $(0.81) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:34 pm

Cantor Fitzgerald has reiterated its Overweight rating on Soleno Therapeutics (NASDAQ:SLNO) and maintained a price target of $67.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 3:54 pm

Soleno Therapeutics has submitted a New Drug Application to the FDA for DCCR extended-release tablets aimed at treating Prader-Willi syndrome in individuals aged four and older with hyperphagia.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:02 pm

Soleno Therapeutics (NASDAQ:SLNO) will join the Russell 3000 Index effective July 1, 2024, as part of the annual reconstitution of the Russell US Indexes.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:26 pm

NVIDIA Corp. (NASDAQ:NVDA) has seen a 186% surge in the past year, driven by high demand for AI chips, making it the third-largest U.S. company by market value. However, seven other U.S. stocks have more than doubled Nvidia's returns over the same period, including Vera Therapeutics, Vertiv Holdings, MicroStrategy, Abercrombie & Fitch, Carvana, Soleno Therapeutics, and MoneyLion.

Portfolio Pulse from Piero Cingari

May 29, 2024 | 9:56 pm

Soleno Therapeutics (NASDAQ:SLNO) will present data on its DCCR extended-release tablets for Prader-Willi Syndrome at the ENDO 2024 conference.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 8:23 pm

Oppenheimer analyst Leland Gershell maintains an Outperform rating on Soleno Therapeutics (NASDAQ:SLNO) but lowers the price target from $65 to $59.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:36 pm

Baird analyst Brian Skorney initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with an Outperform rating and a price target of $72.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 9:19 am

Soleno Therapeutics reported a Q1 2024 adjusted EPS loss of $(0.59), missing the consensus estimate of $(0.37) by 59.46%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.